GFAP and Alzheimer disease: This finding is consistent with a pre-clinical study by Tobey and colleagues who investigated the effect of cOMM on improving the conditions related to AD, such as attenuating amyloid-β levels and reducing levels of activated astrocytes.57 Aged AD animals received cOMM every day for 7 days, with histological analysis revealing an increase in GFAP expression in the DG subregion, which was also observed in this pilot study.